Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 18/20 | 1.00 |
| ▸ | MAPK13 | O15264 | 16/20 | 1.00 |
| ▸ | MAPK12 | P53778 | 16/20 | 1.00 |
| ▸ | MAPK11 | Q15759 | 16/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 1/20 | 1.00 |
| ▸ | HTR2C | P28335 | 1/20 | 1.00 |
| ▸ | ADORA2A | P29274 | 1/20 | 1.00 |
| ▸ | ADORA1 | P30542 | 1/20 | 1.00 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL149547 | 1.00 | MAPK14 (1.00) | MAPK14MAPK13MAPK12MAPK11CYP3A4 | |
| SCHEMBL8706893 | 0.86 | MAPK14 (1.00) | MAPK14MAPK13MAPK12MAPK11CYP3A4 | |
| SCHEMBL8705978 | 0.83 | MAPK14 (1.00) | MAPK14MAPK13MAPK12MAPK11CYP3A4 | |
| SCHEMBL5618524 | 0.82 | MAPK14 (0.70) | MAPK14MAPK13MAPK12MAPK11CYP3A4 | |
| SCHEMBL8709974 | 0.82 | MAPK14 (1.00) | MAPK14MAPK13MAPK12MAPK11CYP3A4 | |
| SCHEMBL14159752 | 0.82 | MAPK14 (0.69) | MAPK14MAPK13MAPK12MAPK11CYP3A4 | |
| SCHEMBL14270472 | 0.81 | MAPK14 (0.67) | MAPK14MAPK13MAPK12MAPK11CYP3A4 | |
| SCHEMBL8705885 | 0.78 | MAPK14 (1.00) | MAPK14MAPK13MAPK12MAPK11CYP3A4 | |
| SCHEMBL6247693 | 0.74 | MAPK14 (1.00) | MAPK14MAPK13MAPK12MAPK11CYP3A4 | |
| SCHEMBL6640436 | 0.74 | MAPK14 (1.00) | MAPK14MAPK13MAPK12MAPK11CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114634575-B | Development and application of complement inhibitor | 康诺亚生物医药科技（成都）有限公司 | 2025-04-11 | — | — | CN | disclosed |
| US-20240228665-A1 | METHODS FOR TREATING CONDITIONS ASSOCIATED WITH MASP-2 DEPENDENT COMPLEMENT ACTIVATION | OMEROS CORPORATION | 2024-07-11 | — | — | US | disclosed |
| US-20240076408-A1 | METHODS FOR TREATING CONDITIONS ASSOCIATED WITH MASP-2 DEPENDENT COMPLEMENT ACTIVATION | OMEROS CORPORATION | 2024-03-07 | — | — | US | disclosed |
| US-20240067751-A1 | DEVELOPMENT AND APPLICATION OF COMPLEMENT INHIBITOR | KEYMED BIOSCIENCES CO.,LTD (CN) | 2024-02-29 | — | — | US | disclosed |
| US-11884742-B2 | Methods for treating conditions associated with MASP-2 dependent complement activation | OMEROS CORPORATION (US) | 2024-01-30 | — | — | US | disclosed |
| US-20230391889-A1 | Methods for Treating Conditions Associated with MASP-2 Dependent Complement Activation | OMEROS CORPORATION | 2023-12-07 | — | — | US | disclosed |
| EP-4265641-A1 | DEVELOPMENT AND APPLICATION OF COMPLEMENT INHIBITOR | Keymed Biosciences Co.,Ltd. (CN) | 2023-10-25 | — | — | EP | disclosed |
| US-RE49219-E1 | Local intraosseous administration of bone forming agents and anti-resorptive agents, and devices therefor | DePuy Synthes Products, Inc. (US) | 2022-09-27 | — | — | US | disclosed |
| WO-2022127834-A1 | DEVELOPMENT AND APPLICATION OF COMPLEMENT INHIBITOR | 康诺亚生物医药科技（成都）有限公司 | 2022-06-23 | — | — | WO | disclosed |
| CN-114634575-A | Development and application of complement inhibitor | 康诺亚生物医药科技（成都）有限公司 | 2022-06-17 | — | — | CN | disclosed |